FDA Approves Empagliflozin for Reducing CVD Death FDA Approves Empagliflozin for Reducing CVD Death

The new indication follows the landmark EMPA-REG trial, the first to show that a diabetes drug could reduce death as well as lower blood glucose.FDA Approvals
Source: Medscape Cardiology Headlines - Category: Cardiology Tags: Diabetes & Endocrinology News Alert Source Type: news